[Prospects of gene therapy for monogenic nephrolithiasis]

Monogenic nephrolithiasis is comparatively rare in clinical practice, but its yearly increasing incidence and impacts on physical and mental health are worth wide attention. At present, management of monogenic nephrolithiasis are still the medication and surgery. This article regards the research progress on primary hyperoxaluria as the breakthrough point to review the etiological therapy of monogenic nephrolithiasis. We aim to promote more studies on other monogenic nephrolithiasis, more methods and drugs for gene therapy, precise and individualized treatment of monogenic nephrolithiasis, and thus to promote the prevention and treatment of monogenic nephrolithiasis in China.